BioCentury
ARTICLE | Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

July 20, 2018 5:13 PM UTC

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630.

Revolution will receive an upfront payment of $50 million and is eligible for more than $500 million in development and regulatory milestones, plus tiered royalties up to mid-double digits in ex-U.S. markets...